Monte Rosa Therapeutics Inc

NASDAQ GLUE

Data sourced from

and

Daily

Download Data

Monte Rosa Therapeutics Inc Share Price on June 03, 2024: USD 3.98

Monte Rosa Therapeutics Inc Share Price is USD 3.98 on June 03, 2024, a -46.29% change year over year. Share price refers to the current trading price of a single share of a company's stock. It represents the monetary value that investors are willing to pay for ownership in the company. Share prices are determined by the supply and demand dynamics in the stock market and can fluctuate throughout the trading day. Changes in share prices are influenced by various factors, including company performance, industry trends, market conditions, investor sentiment, and economic indicators. Share price is a key indicator used by investors to assess the performance and valuation of a company's stock.

Monte Rosa Therapeutics Inc 52-week high Share Price is USD 8.46 on March 25, 2024, which is 112.56% above the current Share Price.
Monte Rosa Therapeutics Inc 52-week low Share Price is USD 2.50 on October 26, 2023, which is -37.19% below the current Share Price.
Monte Rosa Therapeutics Inc average Share Price for the last 52 weeks is USD 5.57.

NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO	Dr. Markus Warmuth M.D.
IPO Date	June 24, 2021
Location	United States
Headquarters	645 Summer Street, Boston, MA, United States, 02210
Employees	130
Sector	Healthcare
Industry	Biotechnology

Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Key trends